Artículos relacionados a Chemo Fog: Cancer Chemotherapy-Related Cognitive Impairment:...
Chemo Fog: Cancer Chemotherapy-Related Cognitive Impairment: 678 (Advances in Experimental Medicine and Biology) - Tapa dura
CANCER PATIENTS HAVE BENEFITTED GREATLY FROM RECENT ADVANCES IN THE DRUGS, DOSE REGIMENS, AND COMBINATIONS USED TO TREAT THEIR PRIMARY TUMOR AND FOR THE TREATMENT OR PREVENTION OF SPREAD OF THEIR DISEASE. DUE TO THE ADVANCES IN CHEMOTHERAPY AND OTHER ASPECTS OF PREVENTION, EARLY DETECTION, AND TREATMENT MODALITIES, AN INCREASING PERCENTAGE OF PATIENTS ARE SURVIVING THE DISEASE. FOR SOME TYPES OF CANCER, THE MAJORITY OF PATIENTS LIVE DECADES BEYOND THEIR DIAGNOSIS. FOR THIS THEY ARE FOREVER THANKFUL AND APPRECIATIVE OF THE DRUGS THAT HELPED LEAD TO THIS INCREASED SURVIVAL RATE. BUT NO DRUG IS DEVOID OF ADVERSE EFFECTS. THIS ALSO APPLIES TO CHEMOTHERAPEUTIC AGENTS. THE ACUTE CYTOTOXIC EFFECTS OF THESE AGENTS ARE WELL KNOWN––INDEED ARE OFTEN REQUIRED FOR THEIR THERAPEUTIC BENEFIT. THE CHRONIC ADVERSE EFFECTS ARE VARIED AND IN SOME CASES LESS WELL KNOWN. WITH THE INCREASE IN SURVIVAL RATES, THERE HAS EMERGED A NEW AWARENESS OF THESE CHRONIC ADVERSE EFFECTS.
"Sinopsis" puede pertenecer a otra edición de este libro.
Reseña del editor:
Cancer patients have benefitted greatly from recent advances in the drugs, dose regimens, and combinations used to treat their primary tumor and for the treatment or prevention of spread of their disease. Due to the advances in chemotherapy and other aspects of prevention, early detection, and treatment modalities, an increasing percentage of patients are surviving the disease. For some types of cancer, the majority of patients live decades beyond their diagnosis. For this they are forever thankful and appreciative of the drugs that helped lead to this increased survival rate. But no drug is devoid of adverse effects. This also applies to chemotherapeutic agents. The acute cytotoxic effects of these agents are well known––indeed are often required for their therapeutic benefit. The chronic adverse effects are varied and in some cases less well known. With the increase in survival rates, there has emerged a new awareness of these chronic adverse effects.
Biografía del autor:
ROBERT B. RAFFA, PhD, is Professor of Pharmacology and Chair of the Department of Pharmaceutical Sciences at Temple University School of Pharmacy in Philadelphia, Pennslyvania. He holds B Chem E and BS degrees in Chemical Engineering and Physiological Psychology, MS degrees in Biomedical Engineering and Toxicology, and a PhD in Pharmacology. He is the co-author or editor of several books on pharmacology and thermodynamics and over 200 articles in refereed journals, and is active in NIH-funded research, editorial, and professional society activities. Dr. Raffa became co-founder and president of the Forget-Me-Not Foundation in 2009. RONALD J. TALLAR IDA, PhD, is a Professor of Pharmacology at Temple University School of Medicine. He has BS and MS degrees in physics/mathematics from Drexel University and a PhD in pharmacology. His work, primarily concerned with quantitative aspects of pharmacology, is represented in more than 250 published works that include eight books he has authored or co-authored. Dr. Tallarida currently teaches, serves on editorial advisory boards, conducts NIH-funded research, and is active in professional societies. Dr. Tallarida became co-founder and Vice-president of the Forget-Me-Not Foundation in 2009.
"Sobre este título" puede pertenecer a otra edición de este libro.
- EditorialSpringer-Verlag New York Inc.
- Año de publicación2010
- ISBN 10 1441963057
- ISBN 13 9781441963055
- EncuadernaciónTapa dura
- Número de páginas216
- EditorRaffa Robert B., Tallarida Ronald J.
Comprar nuevo
Ver este artículo
EUR 171,33
Gastos de envío:
EUR 3,72
A Estados Unidos de America
Los mejores resultados en AbeBooks
Imagen de archivo
Chemo Fog: Cancer Chemotherapy-Related Cognitive Impairment (Advances in Experimental Medicine and Biology, 678)
Publicado por
Springer
(2010)
ISBN 10: 1441963057
ISBN 13: 9781441963055
Nuevo
Tapa dura
Cantidad disponible: 1
Librería:
Valoración
Descripción Condición: New. Nº de ref. del artículo: ABLIING23Mar2411530297041
Comprar nuevo
EUR 171,33
Convertir moneda
Imagen del vendedor
Chemo Fog
Publicado por
SPRINGER NATURE Jun 2010
(2010)
ISBN 10: 1441963057
ISBN 13: 9781441963055
Nuevo
Tapa dura
Cantidad disponible: 1
Librería:
Valoración
Descripción Buch. Condición: Neu. This item is printed on demand - it takes 3-4 days longer - Neuware -Cancer patients have benefitted greatly from recent advances in the drugs, dose regimens, and combinations used to treat their primary tumor and for the treatment or prevention of spread of their disease. Due to the advances in chemotherapy and other aspects of prevention, early detection, and treatment modalities, an increasing percentage of patients are surviving the disease. For some types of cancer, the majority of patients live decades beyond their diagnosis. For this they are forever thankful and appreciative of the drugs that helped lead to this increased survival rate. But no drug is devoid of adverse effects. This also applies to chemotherapeutic agents. The acute cytotoxic effects of these agents are well known--indeed are often required for their therapeutic benefit. The chronic adverse effects are varied and in some cases less well known. With the increase in survival rates, there has emerged a new awareness of these chronic adverse effects. 216 pp. Englisch. Nº de ref. del artículo: 9781441963055
Comprar nuevo
EUR 160,49
Convertir moneda
Gastos de envío:
EUR 23,00
De Alemania a Estados Unidos de America
Destinos, gastos y plazos de envío
Imagen del vendedor
Chemo Fog
Publicado por
Springer New York
(2010)
ISBN 10: 1441963057
ISBN 13: 9781441963055
Nuevo
Tapa dura
Cantidad disponible: > 20
Librería:
Valoración
Descripción Condición: New. Nº de ref. del artículo: 4176028
Comprar nuevo
EUR 142,49
Convertir moneda
Gastos de envío:
EUR 48,99
De Alemania a Estados Unidos de America
Destinos, gastos y plazos de envío
Imagen del vendedor
Chemo Fog : Cancer Chemotherapy-Related Cognitive Impairment
Publicado por
Springer Nature Singapore
(2010)
ISBN 10: 1441963057
ISBN 13: 9781441963055
Nuevo
Tapa dura
Cantidad disponible: 2
Librería:
Valoración
Descripción Buch. Condición: Neu. Druck auf Anfrage Neuware - Printed after ordering - Cancer patients have benefitted greatly from recent advances in the drugs, dose regimens, and combinations used to treat their primary tumor and for the treatment or prevention of spread of their disease. Due to the advances in chemotherapy and other aspects of prevention, early detection, and treatment modalities, an increasing percentage of patients are surviving the disease. For some types of cancer, the majority of patients live decades beyond their diagnosis. For this they are forever thankful and appreciative of the drugs that helped lead to this increased survival rate. But no drug is devoid of adverse effects. This also applies to chemotherapeutic agents. The acute cytotoxic effects of these agents are well known--indeed are often required for their therapeutic benefit. The chronic adverse effects are varied and in some cases less well known. With the increase in survival rates, there has emerged a new awareness of these chronic adverse effects. Nº de ref. del artículo: 9781441963055
Comprar nuevo
EUR 164,03
Convertir moneda
Gastos de envío:
EUR 32,99
De Alemania a Estados Unidos de America
Destinos, gastos y plazos de envío
Imagen de archivo
Chemo Fog: Cancer Chemotherapy-related Cognitive Impairment: Vol 678
Publicado por
Springer Verlag
(2010)
ISBN 10: 1441963057
ISBN 13: 9781441963055
Nuevo
Tapa dura
Cantidad disponible: 2
Librería:
Valoración
Descripción Hardcover. Condición: Brand New. illustrated edition. 216 pages. 10.00x6.50x0.50 inches. In Stock. Nº de ref. del artículo: x-1441963057
Comprar nuevo
EUR 207,45
Convertir moneda
Gastos de envío:
EUR 11,83
De Reino Unido a Estados Unidos de America
Destinos, gastos y plazos de envío
Imagen del vendedor
Chemo Fog (Hardcover)
Publicado por
Springer-Verlag New York Inc., New York, NY
(2010)
ISBN 10: 1441963057
ISBN 13: 9781441963055
Nuevo
Tapa dura
Cantidad disponible: 1
Librería:
Valoración
Descripción Hardcover. Condición: new. Hardcover. Cancer patients have benefitted greatly from recent advances in the drugs, dose regimens, and combinations used to treat their primary tumor and for the treatment or prevention of spread of their disease. Due to the advances in chemotherapy and other aspects of prevention, early detection, and treatment modalities, an increasing percentage of patients are surviving the disease. For some types of cancer, the majority of patients live decades beyond their diagnosis. For this they are forever thankful and appreciative of the drugs that helped lead to this increased survival rate. But no drug is devoid of adverse effects. This also applies to chemotherapeutic agents. The acute cytotoxic effects of these agents are well knownindeed are often required for their therapeutic benefit. The chronic adverse effects are varied and in some cases less well known. With the increase in survival rates, there has emerged a new awareness of these chronic adverse effects. Cancer patients have benefitted greatly from recent advances in the drugs, dose regimens, and combinations used to treat their primary tumor and for the treatment or prevention of spread of their disease. With the increase in survival rates, there has emerged a new awareness of these chronic adverse effects. Shipping may be from our UK warehouse or from our Australian or US warehouses, depending on stock availability. Nº de ref. del artículo: 9781441963055
Comprar nuevo
EUR 226,11
Convertir moneda
Gastos de envío:
EUR 43,79
De Reino Unido a Estados Unidos de America
Destinos, gastos y plazos de envío